tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Apr;18(4):e13288.
doi: 10.1111/irv.13288. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season
Mahrukh Imran[SUP] 1 [/SUP], Joan Puig-Barbera[SUP] 2 [/SUP], Justin R Ortiz[SUP] 3 [/SUP], Lorena Lopez-Gonzalez[SUP] 4 [/SUP], Alex Dean[SUP] 4 [/SUP], Machaon Bonafede[SUP] 4 [/SUP], Mendel D M Haag[SUP] 5 [/SUP]
Affiliations
Background: Adults ≥ 65 years of age have suboptimal influenza vaccination responses compared to younger adults due to age-related immunosenescence. Two vaccines were specifically developed to enhance protection: MF59-adjuvanted trivalent influenza vaccine (aIIV3) and high-dose egg-based trivalent influenza vaccine (HD-IIV3e).
Methods: In a retrospective cohort study conducted using US electronic medical records linked to claims data during the 2019-2020 influenza season, we compared the relative vaccine effectiveness (rVE) of aIIV3 with HD-IIV3e and a standard-dose non-adjuvanted egg-based quadrivalent inactivated influenza vaccine (IIV4e) for the prevention of cardiorespiratory hospitalizations, including influenza hospitalizations. We evaluated outcomes in the "any" diagnosis position and the "admitting" position on the claim. A doubly robust methodology using inverse probability of treatment weighting and logistic regression was used to adjust for covariate imbalance. rVE was calculated as 100 * (1 - OR[SUB]adjusted[/SUB]).
Results: The study included 4,299,594 adults ≥ 65 years of age who received aIIV3, HD-IIV3e, or IIV4e. Overall, aIIV3 was associated with lower proportions of cardiorespiratory hospitalizations with diagnoses in any position compared to HD-IIV3e (rVE = 3.9% [95% CI, 2.7-5.0]) or IIV4e (9.0% [95% CI, 7.7-10.4]). Specifically, aIIV3 was more effective compared with HD-IIV3e and IIV4e in preventing influenza hospitalizations (HD-IIV3e: 9.7% [95% CI, 1.9-17.0]; IIV4e: 25.3% [95% CI, 17.7-32.2]). Consistent trends were observed for admitting diagnoses.
Conclusion: Relative to both HD-IIV3e and IIV4e, aIIV3 provided improved protection from cardiorespiratory or influenza hospitalizations.
Keywords: adjuvanted influenza vaccine; high‐dose influenza vaccine; hospitalizations; influenza; ischemic stroke; myocardial infarction; older adults; pneumonia; quadrivalent inactivated influenza vaccine; relative vaccine effectiveness.
. 2024 Apr;18(4):e13288.
doi: 10.1111/irv.13288. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season
Mahrukh Imran[SUP] 1 [/SUP], Joan Puig-Barbera[SUP] 2 [/SUP], Justin R Ortiz[SUP] 3 [/SUP], Lorena Lopez-Gonzalez[SUP] 4 [/SUP], Alex Dean[SUP] 4 [/SUP], Machaon Bonafede[SUP] 4 [/SUP], Mendel D M Haag[SUP] 5 [/SUP]
Affiliations
- PMID: 38644564
- PMCID: PMC11033326
- DOI: 10.1111/irv.13288
Background: Adults ≥ 65 years of age have suboptimal influenza vaccination responses compared to younger adults due to age-related immunosenescence. Two vaccines were specifically developed to enhance protection: MF59-adjuvanted trivalent influenza vaccine (aIIV3) and high-dose egg-based trivalent influenza vaccine (HD-IIV3e).
Methods: In a retrospective cohort study conducted using US electronic medical records linked to claims data during the 2019-2020 influenza season, we compared the relative vaccine effectiveness (rVE) of aIIV3 with HD-IIV3e and a standard-dose non-adjuvanted egg-based quadrivalent inactivated influenza vaccine (IIV4e) for the prevention of cardiorespiratory hospitalizations, including influenza hospitalizations. We evaluated outcomes in the "any" diagnosis position and the "admitting" position on the claim. A doubly robust methodology using inverse probability of treatment weighting and logistic regression was used to adjust for covariate imbalance. rVE was calculated as 100 * (1 - OR[SUB]adjusted[/SUB]).
Results: The study included 4,299,594 adults ≥ 65 years of age who received aIIV3, HD-IIV3e, or IIV4e. Overall, aIIV3 was associated with lower proportions of cardiorespiratory hospitalizations with diagnoses in any position compared to HD-IIV3e (rVE = 3.9% [95% CI, 2.7-5.0]) or IIV4e (9.0% [95% CI, 7.7-10.4]). Specifically, aIIV3 was more effective compared with HD-IIV3e and IIV4e in preventing influenza hospitalizations (HD-IIV3e: 9.7% [95% CI, 1.9-17.0]; IIV4e: 25.3% [95% CI, 17.7-32.2]). Consistent trends were observed for admitting diagnoses.
Conclusion: Relative to both HD-IIV3e and IIV4e, aIIV3 provided improved protection from cardiorespiratory or influenza hospitalizations.
Keywords: adjuvanted influenza vaccine; high‐dose influenza vaccine; hospitalizations; influenza; ischemic stroke; myocardial infarction; older adults; pneumonia; quadrivalent inactivated influenza vaccine; relative vaccine effectiveness.